Area under the receiver operating characteristic curves (AUCs) determined the discriminatory ability of all measures to classify individuals as having no AMD or iAMD and to differentiate iAMD from its neighboring disease states. Main Outcomes and Measures: Intraclass correlation coefficients (ICCs) and Bland-Altman 95% limits of agreement (LoA) were computed to assess repeatability. Participants with early AMD, iAMD, late AMD, and no AMD were recruited. VF assessments were performed on day 0 and day 14. The repeatability and discriminatory power of 5 simple chart-based assessments of VF (best-corrected visual acuity, low-luminance visual acuity, Moorfields Acuity Test, Pelli-Robson Contrast Sensitivity, and International Reading Speed Test ) were assessed in a repeated-measures design. Participants with no AMD and early AMD were recruited from hospital staff, friends, and family of participants with AMD and via referrals from community ophthalmologists and optometrists. Participants were recruited between April 2018 and March 2020 and were identified during routine clinical review.
Design, Setting, and Participants: This international noninterventional study took place at 18 tertiary ophthalmology departments across Europe.
Irest capsules trial#
Objective: To assess the reliability and discriminatory power of 5 simple chart-based visual function (VF) tests as potential measures for clinical trial end points with regulatory and patient-access intention in intermediate AMD (iAMD). Importance: There is a need for validated clinical end points that are reliably able to quantify potential therapeutic effects of future treatments targeting age-related macular degeneration (AMD) before the onset of serious visual impairment.